Alterity Therapeutics provides corporate update

Alterity Therapeutics (ATHE) released its Appendix 4C Quarterly Cash Flow Report and update on company activities for the quarter ending 31 December 2025. Key highlights: Phase 2 data for ATH434 in Multiple System Atrophy strengthened by additional analyses and multiple international scientific presentations during the quarter. Regulatory planning activities advancing toward a Phase 3 program, including preparation for FDA End-Of-Phase-2 meeting in mid-2026. Ongoing partnering and strategic discussions with pharmaceutical companies and corporate advisers to explore non-dilutive pathways to fund Phase 3 development. Board and executive leadership strengthened to support Alterity through its next stage of clinical development, partnering and commercial planning. Cash balance of A$49.2 million at 31 December 2025.